B
First Tracks Biotherapeutics, I — Earnings Quality Grade B
TRAX · Healthcare
Generally healthy
Revenue
$0M
2024
Net Income
-$164M
2024
Gross Margin
—
Free Cash Flow
-$126M
01
Screening Summary
6
Passed
3
Watch
0
Failed
—
M-Score
Management Signals
Source: SEC EDGAR 8-K Item 5.02, with exhibit links when available
02
Financial Trends
Revenue & Net Income ($B)
Margins (%)
03
18-Point Screening
01
Revenue Quality
—
A1DSO Change
Insufficient data
—
A2AR vs Revenue Growth
Insufficient data
—
A3Revenue vs CFFO
Insufficient data
02
Expense Quality
✓
B1Inventory vs COGS
No material inventory
—
B2CapEx vs Revenue
Insufficient data
—
B3SG&A Ratio
Insufficient data
—
B4Gross Margin
Insufficient data
03
Cash Flow Quality
!
C1CFFO vs Net Income
CFFO/NI = 0.77. Below 1.0
!
C2Free Cash Flow
FCF is negative ($-0.1B)
✓
C3Accruals Ratio
Accruals ratio = -8.6%. Low accruals
✓
C4Cash vs Debt
Cash $0.4B covers debt $0.0B
04
Balance Sheet Health
✓
D1Goodwill + Intangibles
No goodwill. Clean balance sheet
✓
D2Leverage
Debt/EBITDA = -0.1x. Healthy
—
D3Soft Asset Growth
Insufficient data
—
D4Asset Impairment
No write-off data
05
Acquisition Risk
!
E1Serial Acquirer FCF
FCF after acquisitions negative for 2/3 years
✓
E2Goodwill Surge
No goodwill
06
Manipulation Score
—
F1Beneish M-Score
Insufficient data
05
Altman Z-Score
10.67
Safe Zone0 Distress1.102.605.0+ Safe
0.8005
Liquidity
0
Cumulative profit
-0.4098
Operating efficiency
7.786
Leverage
Generated from public financial data using forensic accounting frameworks. Not investment advice. Data: Yahoo Finance · 2026-04-25